Trends in the treatment outcomes for advanced colorectal cancer: An analysis at a single community hospital in Japan

Morimasa Tomikawa, Daisuke Korenaga, Tomohiko Akahoshi, Kenichi Kohshi, Keishi Sugimachi, Yasuharu Ikeda, Kenji Takenaka, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Purpose: To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan. Methods: We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992-2000, n = 258]; Group B [2001-2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients. Results: The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05). Conclusions: Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.

元の言語英語
ページ(範囲)801-805
ページ数5
ジャーナルSurgery today
41
発行部数6
DOI
出版物ステータス出版済み - 6 1 2011

Fingerprint

Community Hospital
Colorectal Neoplasms
Japan
Survival Rate
Leucovorin
Urban Hospitals
Fluorouracil
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery

これを引用

Trends in the treatment outcomes for advanced colorectal cancer : An analysis at a single community hospital in Japan. / Tomikawa, Morimasa; Korenaga, Daisuke; Akahoshi, Tomohiko; Kohshi, Kenichi; Sugimachi, Keishi; Ikeda, Yasuharu; Takenaka, Kenji; Maehara, Yoshihiko.

:: Surgery today, 巻 41, 番号 6, 01.06.2011, p. 801-805.

研究成果: ジャーナルへの寄稿記事

Tomikawa, M, Korenaga, D, Akahoshi, T, Kohshi, K, Sugimachi, K, Ikeda, Y, Takenaka, K & Maehara, Y 2011, 'Trends in the treatment outcomes for advanced colorectal cancer: An analysis at a single community hospital in Japan', Surgery today, 巻. 41, 番号 6, pp. 801-805. https://doi.org/10.1007/s00595-010-4348-3
Tomikawa, Morimasa ; Korenaga, Daisuke ; Akahoshi, Tomohiko ; Kohshi, Kenichi ; Sugimachi, Keishi ; Ikeda, Yasuharu ; Takenaka, Kenji ; Maehara, Yoshihiko. / Trends in the treatment outcomes for advanced colorectal cancer : An analysis at a single community hospital in Japan. :: Surgery today. 2011 ; 巻 41, 番号 6. pp. 801-805.
@article{2abf34ca548645c6914df7ce2730f41b,
title = "Trends in the treatment outcomes for advanced colorectal cancer: An analysis at a single community hospital in Japan",
abstract = "Purpose: To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan. Methods: We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992-2000, n = 258]; Group B [2001-2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients. Results: The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9{\%} vs 3.9{\%}, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0{\%} vs 13.3{\%}, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0{\%} vs 21.0{\%}, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05). Conclusions: Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.",
author = "Morimasa Tomikawa and Daisuke Korenaga and Tomohiko Akahoshi and Kenichi Kohshi and Keishi Sugimachi and Yasuharu Ikeda and Kenji Takenaka and Yoshihiko Maehara",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s00595-010-4348-3",
language = "English",
volume = "41",
pages = "801--805",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Trends in the treatment outcomes for advanced colorectal cancer

T2 - An analysis at a single community hospital in Japan

AU - Tomikawa, Morimasa

AU - Korenaga, Daisuke

AU - Akahoshi, Tomohiko

AU - Kohshi, Kenichi

AU - Sugimachi, Keishi

AU - Ikeda, Yasuharu

AU - Takenaka, Kenji

AU - Maehara, Yoshihiko

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Purpose: To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan. Methods: We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992-2000, n = 258]; Group B [2001-2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients. Results: The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05). Conclusions: Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.

AB - Purpose: To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan. Methods: We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992-2000, n = 258]; Group B [2001-2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients. Results: The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05). Conclusions: Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.

UR - http://www.scopus.com/inward/record.url?scp=79960307666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960307666&partnerID=8YFLogxK

U2 - 10.1007/s00595-010-4348-3

DO - 10.1007/s00595-010-4348-3

M3 - Article

C2 - 21626326

AN - SCOPUS:79960307666

VL - 41

SP - 801

EP - 805

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 6

ER -